Background: The native mitral lesion of active infective endocarditis implies a poor prognosis and is associated with adverse short-or long-term results without surgical treatment. Both mitral valvuloplasty (MVP) and mitral valve replacement (MVR) have been performed in the treatment of active native mitral infective endocarditis (ANMIE). However, the outcomes of the two approaches remain unclear. The aim of this study was to systematically review the two procedures with mortality and survival as the primary endpoints. Methods: A systematic review of the literature was conducted to identify all relevant studies with comparative data on MVP versus MVR for the treatment of ANMIE. Information on baseline characteristics of patients, operation method, quality of literature, follow-up, and so forth was abstracted using standardized protocols. Pooled odds ratio (OR) or hazard ratio (HR) was calculated and possible publication bias was tested. Results: Nine comparative observational studies with a total of 633 patients (MVP ¼ 265, MVR ¼ 368) were identified for qualitative assessment, data extraction, and analysis. The summary OR for operative mortality, comparing repair with replacement, was 0.37 (95% CI 0.0.18e0.80; p ¼ 0.0005). Summary 1-and 5-year HRs for event-free survival were 0.43 (95% CI 0.20e0.92; p ¼ 0.03) and 0.44 (95% CI 0.25e0.77, p ¼ 0.004), respectively (repair vs. replacement). Summary 1-and 5-year survival HRs were 0.51 (95% CI 0.24e1.08; p ¼ 0.08) and 0.55 (95% CI 0.32e0.96; p ¼ 0.004), respectively (repair vs. replacement). No heterogeneity was revealed between studies, and possible publication bias was insignificant. Conclusions: This meta-analysis suggests that MVP may be associated with superior postoperative survival outcomes compared with MVR. MVP is desirable, if possible, as a durable alternative to replacement. However, we must consider the influence of different patient characteristics and surgeons' preferences on the choice of surgical approach, and additional powered clinical trials will be required to confirm these findings.
Introduction
The mortality rates for the medical treatment of infective endocarditis range from 60% to 90%, and effective surgical treatment can greatly reduce the mortality of patients by 8e16%. 1, 2 Recently, some studies on active infective endocarditis have posited that mitral valve repair (MVP) was associated with lower postoperative mortality and complications than mitral replacement (MVR), but the results were not consistent. 3 Here, we undertook a systematic review and metaanalysis to estimate the clinical results of patients who underwent MVP or MVR for active native mitral infective endocarditis (ANMIE).
Methods

Data collection
The meta-analysis was performed according to the PRISMA guidelines. 4 A literature review (from 1995 to 2015,
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in Chinese and English) was conducted whereby the following databases were searched: PubMed, EMBASE, Cochrane Library, Chinese Biomedical Literature (CBM), Wanfang, and Chinese National Knowledge infrastructure (CNKI) databases. The search strategy in English used the following free text words and MeSH (medical subject headings) terms: active infectious endocarditis, native mitral valve, mitral valve repair, mitral valvuloplasty, and mitral replacement. The same (translated) key words were used to search the Chinese literature. To enhance detection, we also manually searched reviews and literature included in the references, in addition to assembled academic conference papers and degree theses.
Data inclusion criteria
Eligible studies were required to meet the following inclusion criteria. (1) The study includes both repair and replacement groups, and the number of patients who underwent cardiac surgery was available. (2) Patients with ANMIE received a definite diagnosis of infective endocarditis according to the modified Duke criteria. 5 ANMIE was defined as endocarditis with at least one of the following: positive blood cultures, fever, leukocytosis, raised inflammation markers, or current antibiotic treatment. 6 (3) Outcome indicators included in-hospital mortality rate (30 days postoperatively), survival rate, and event-free survival rate (no recurrence, no operation).
Data exclusion criteria
We chose only those studies judged the best from repeated published literature. Studies were excluded when (1) an overlap between authors or centers in the published literature existed; (2) literature qualitative score was less than 6; (3) postoperative follow-up data were not provided; (4) only one of the two procedures was included in the studies.
Data extraction
Two researchers (Jinzhou Liu, Xiaofeng Li) extracted data independently using a standard data extraction form and mutual checks. Disagreement was resolved by consensus with a third investigator. The data extraction template contains general information: first author, time of publication, time of study, types of study design, baseline demographics, interventions, followup, outcome data, and evaluation score of the bias risk. We calculated the appropriate measure of effect by means of raw data in literature if no odds ratios (ORs) and/or hazard ratios (HRs) were available from the original articles. 
Quality assessment of literature
Each study was evaluated by two researchers to estimate study bias according to the following scoring grade, for discussion in cases of debate and in seeking third-party recommendations. We created a scoring scale consisting of five aspects by referring to the NewcastleeOttawa Scale. 8 2 value of greater than 50% were considered as a measure of severe heterogeneity, the randomeffects model was employed; otherwise the fixed model was used. Publication bias was assessed using funnel plots comparing log risk estimates with their standard error. Egger's linear regression method and Begg's rank correlation test were utilized to detect funnel plot asymmetry. 9, 10 3. Results
Description of the studies
The search process generated 870 publications, of which 42 were filtered out. Using the data inclusion and exclusion criteria, ten full-text articles were retrieved for detailed information, one of which scored less than 6 points after assessment. Ultimately, a total of eight English articles 11e18 and one Chinese article 19 were included in the metaanalysis. Fig. 1 reveals the study selection process in accordance with PRISMA. The general situation of included studies is presented in Table 1 . The nine eligible studies were observational analyses and included 633 patients, of whom 265 underwent mitral valvuloplasty and the other 368 mitral valve replacement. Follow-up rate was more than 98%; quality assessment of bias risk score was more than 7 in nine included studies.
Clinical characteristics of included studies
Clinical characteristics of the included studies are listed in Table 2 . Pooled effect sizes were calculated by RevMan Manager Version 5.3. Five series (324 patients) provided data regarding the mean age.
15e19 the pooled effect size estimate suggested that the mean age was increased 4.61 years in the replacement group (95% CI À8.05e1.17; p ¼ 0.09). There was no evidence of heterogeneity ( p ¼ 0.24, I
2 ¼ 28%). Information comparing EuroSCORE II was provided by two studies (128 patients). 15, 18 Euro-SCORE II was 8.5 ± 3.7 in the repair group and 9.0 ± 3.3 in the replacement group (MD À1.49; 95% CI À2.62eÀ0.35; heterogeneity: p ¼ 0.81, I
2 ¼ 0% 2 ¼ 56%). There were no significant differences between the two surgical techniques with regard to other clinical characteristics. 
In-hospital mortality
All nine studies reported operative mortality for ANMIE.
11e19 Forest plots were created using RevMan 5.3, which showed no overall heterogeneity ( p ¼ 0.80, I
2 ¼ 0%). Under fixed-effects modeling the merged data showed overall statistical significance (OR 0.37, 95% CI 0.18e0.75, p ¼ 0.005), illustrating that MVP was associated with a lower incidence of operative mortality (Fig. 2) . Assessment of publication bias by visual examination of the funnel plot (Fig. 3) and by application of Egger's linear regression method ( p ¼ 0.12) and Begg's rank correlation test ( p ¼ 0.61) indicated no significant publication bias.
Event-free survival
Information comparing 1-year or 5-year event-free survival for ANMIE was provided by four studies. 11, 15, 16, 18 The four studies (288 patients; MVP n ¼ 126; MVR n ¼ 162) were used for this meta-analysis (Fig. 4) . Forest plots were created using RevMan5.3 (Figs. 4 and 5), which revealed no significant difference among 1-year event-free survival rates (heterogeneity: p ¼ 0.89, I
2 ¼ 0%; HR 0.43, 95% CI 0.20e0.92, p ¼ 0.03). Neither Begg's rank correlation test ( p ¼ 0.3333) nor Egger's linear regression method ( p ¼ 0.3158) suggested that publication bias was a significant factor when 1-year event-free survival was selected as an endpoint.
Meta-analysis shows a significant difference between the two groups regarding 5-year event-free survival (Fig. 5 ) (heterogeneity: p ¼ 0.58, I
2 ¼ 0%; HR 0.44, 95% CI 0.25e0.77, p ¼ 0.004). In addition, statistical analysis revealed no evidence of significant publication bias (Egger's linear regression method, p ¼ 0.8589; Begg's rank correlation test, p ¼ 1.0000).
Survival
Only five studies reported 1-year survival rates for ANMIE. 13,14,16e18 Forest plots created by RevMan5.3 ( Fig. 6 ) revealed no distinct difference among 1-year survival (no heterogeneity; fixed-effects model HR 0.51, 95% CI 0.24e1.08, p ¼ 0.08). Publication bias was not found to significantly influence results for 1-year survival (Egger's linear regression method, p ¼ 0.6208; Begg's rank correlation test, p ¼ 0.8167).
Six studies reported 5-year survival rates for ANMIE 12e14, [16] [17] [18] (Fig. 7) . The merged results illustrate that there was a distinct difference between the two groups with regard to 5-year survival (no heterogeneity; fixed-effects model HR 0.55, 95% CI 0.32e0.96, p ¼ 0.04). Besides, the p value for Egger's test and Begg's rank test was 0.0321 and 0.4694, respectively, suggesting no significant publication bias.
Discussion
MVP was deemed the preferred surgical method for the treatment of degenerative mitral regurgitation, resulting in potential benefits in comparison with MVR. 20 A recent metaanalysis of ischemic mitral regurgitation showed that MVP was associated with reduced perioperative and late mortality compared with MVR, despite an increased recurrence of at least moderate mitral regurgitation at follow-up. 21 This suggests that different etiologies of mitral disease may have different effects on the outcome of MVP or MVR.
As postoperative reoccurrence of ANMIE is of constant concern, extensive resection of the focus of infection and MVR is considered the preferable operative method. However, because the grafts are susceptible to becoming another source Fig. 2 . Forest plots of the meta-analysis depicting operative mortality of ANMIE. of infection, MVP offers a more precise option for overcoming this shortcoming, and is being performed by an increasing number of clinicians. Some clinical reports 17, 18 have stated that MVP has better short-and long-term results for ANMIE, although these advantages have not yet been confirmed because of the lack of prospective randomized controlled studies. However, a prospective randomized controlled study does not comply with ethical requirements. A general understanding by clinicians of the treatment effects of these two forms of surgical intervention is helpful in making the appropriate decision.
The two main approaches to mitral valve surgery are repair and replacement; in the active infective endocarditis setting, a few cohort studies have compared the outcomes of mitral valve repair with replacement directly and clinical results were still controversial. It is commonly accepted that the choice of MVR or valvoplasty is markedly related to level of hospital diagnosis and treatment and the doctor's preferences. A systematic review of literature by Harm et al . 22 included 24 studies evaluating MVR or MVP in patients with infective endocarditis. This kind of introduced bias accounts for a large proportion of the whole statistical bias. To reduce bias, we therefore collected data from studies eligible that met the criteria, which includes both repair and replacement groups and the number of patients who underwent cardiac surgery. The purpose of this study is to utilize existing data to conduct a systematic evaluation of the situations involving MVP and MVR for the treatment of ANMIE.
This meta-analysis included nine publications from China and abroad, all based on observational study. Of the 633 cases in total, 265 were mitral valvuloplasties and 368 were MVRs. The meta-analysis showed that in the surgical treatment of ANMIE, MVP had lower hospital mortality than MVR. Although there was no discernible difference in 1-year postoperative survival rates, there was a distinct difference in event-free survival rates at 1 and 5 years and the survival rate at 5 years. In other words, the curative effect and follow-up of MVP are as good as those of MVR, with less mortality 5 years postoperatively, implying that mitral repair has a lesser risk for reoperation or infection recurrence during long-term followup. Since no significant heterogeneity was tested across studies, this confirms the robustness of the findings across trials.
High-resistance species included Staphylococcus, Enterococcus, fungal and so forth. We included the data of Staphylococcus from 8 published studies in Table 2 , the statistical results of which showed OR ¼ 1.47 [0.79, 2.73] and P ¼ 0.005. Because of the more severe symptoms in patients with staphylococcal infection, they are more likely to be diagnosed early and more likely to receive MVP. Patients with fungal endocarditis in our included studies were too few in number to enable statistical analysis.
In MVP group, operative results are associated with various mitral valvuloplasty techniques, including repair of the leaflets with native pericardial patch/bovine pericardium and use of artificial chordae, artificial ring, or band. In MVR group, choice of mechanical prosthesis or bio-prosthesis also affects long term survival, especially in elder or heavy diseased patients. We collected data to show that different methods were covered over various periods in different studies between 1997 and 2015. To reduce bias, we collected eligible studies that met our criteria, including both repair and replacement groups and the number of patients who underwent cardiac surgery. We tried to perform statistical analysis for various methods, but this was very difficult because of the limited number of patients. Thus a larger number of clinical cases will be required for statistical power. We will keep track of clinical progress in this area for future analysis.
There are several limitations to the current meta-analysis that should be considered, while interpreting the results with caution. First, all included studies were observational analyses, implying that potential biases existed, although the studies had higher quality (!7 points) and no evidence of significant publication bias. Second, as far as our pooled results were concerned, the choice of surgical methods were related to cardiac function, age, extent of chordal rupture, and Euro-SCORE II, indicating that high-risk patients with multiple comorbidities and poor baseline function are often preferentially allocated to MVR rather than MVP in clinical practice. We recognize that there are substantial differences between the literature results, patient group properties, disease severity, and type of surgical technology available, and that MVP can be feasibly performed only by expert surgeons for selected patients. As a result, the confounding factors may bring about implementation bias. Third, there are numerous indicators in the published literature to be assessed, but in our meta-analysis, taking into account the comparability, fewer outcome indicators were used, a result of which was that the conclusions were not so informative in comparison with published studies. Finally, although statistical analysis revealed no evidence of significant publication bias in the present meta-analysis, such bias remains a possibility, with potentially more favorable results being reported from largevolume expert centers that may not be representative of all institutions. Otherwise, there probably remains unpublished and/or unobtained "gray" literature leading to publication bias, despite the scope of our search being wide.
Despite its unavoidable limitations, this meta-analysis provides, to some extent, a clinical reference point. The choice of operative procedures should be based on the situation of each individual patient and the surgeon's preferences. Our meta-analysis does show that MVP is feasible and may achieve good postoperative results for ANMIE.
In conclusion, this meta-analysis indicates that MVP for ANMIE may improve postoperative outcomes and that MVP may be associated with superior postoperative survival. However, we should acknowledge the influence of different patient characteristics and surgeons' preferences on the choice of surgical approach. MVP is desirable if possible as a durable alternative to replacement. Additional powered clinical trials will be required to confirm these findings.
